Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8779804 | 0.86 | KDM4E (0.38) | ALDH1A1TDP1KDM4E | |
| SCHEMBL25118403 | 0.77 | KDM4E (0.35) | CYP2A6MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL7938138 | 0.74 | ALDH1A1 (0.36) | MAOAMAOBSMN1; SMN2ALDH1A1FBP1 | |
| SCHEMBL7940598 | 0.74 | NR1H2 (0.50) | ALDH1A1ALOX15TDP1KDM4E | |
| SCHEMBL381447 | 0.74 | ALDH1A1 (0.58) | CYP2A6MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4411163 | 0.74 | SLC6A4 (0.45) | CYP2A6MAOAMAOBHAO1SMN1; SMN2 | |
| SCHEMBL8486201 | 0.74 | IDO1 (0.39) | ALDH1A1TDP1KDM4E | |
| SCHEMBL1260200 | 0.70 | CYP2A6 (0.38) | CYP2A6MAOAMAOBHAO1SMN1; SMN2 | |
| SCHEMBL21299983 | 0.70 | CYP2A6 (0.38) | CYP2A6MAOAMAOBHAO1SMN1; SMN2 | |
| SCHEMBL18967981 | 0.70 | CYP2A6 (0.38) | CYP2A6MAOAMAOBHAO1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181270-B2 | Method of making sulfide compounds | UNIVERSAL DISPLAY CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181270-B2 | Method of making sulfide compounds | UNIVERSAL DISPLAY CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181270-B2 | Method of making sulfide compounds | UNIVERSAL DISPLAY CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150246928-A1 | METHOD OF MAKING SULFIDE COMPOUNDS | UNIVERSAL DISPLAY CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246928-A1 | METHOD OF MAKING SULFIDE COMPOUNDS | UNIVERSAL DISPLAY CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246928-A1 | METHOD OF MAKING SULFIDE COMPOUNDS | UNIVERSAL DISPLAY CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| EP-0742201-B1 | PROCESS FOR PRODUCING AROMATIC OR HETEROAROMATIC SULFUR COMPOUNDS | SUMITOMO SEIKA CHEMICALS (JP) | 2003-02-05 | — | — | EP | disclosed |
| CN-1076346-C | Process for preparing aromatic or heteroaromatic sulfur compounds | SUMITOMO SEIKA CHEMICALS (JP) | 2001-12-19 | — | — | CN | disclosed |
| US-5932731-A | HYDROLYZING A HETEROAROMATIC HALOGENATED METHYL SULFIDE IN PRESENCE OF AN ACID | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5741933-A | HYDROLYSIS; OXIDATION | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1998-04-21 | — | — | US | disclosed |
| EP-0770599-A1 | PROCESS FOR THE PREPARATION OF AROMATIC OR HETEROAROMATIC SULFONYL HALIDES | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| CN-1139428-A | Process for producing aromatic or heteroaromatic sulfur compounds | SUMITOMO SEIKA CHEMICALS (JP) | 1997-01-01 | — | — | CN | disclosed |
| EP-0742201-A1 | PROCESS FOR PRODUCING AROMATIC OR HETEROAROMATIC SULFUR COMPOUNDS | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246928-A1 | METHOD OF MAKING SULFIDE COMPOUNDS | CBS, SCLY, QSOX1 | CYP2A6 874/4885MAOA 1646/4885MAOB 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.